MGMartha L. Graber

Martha L. Graber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martha L. Graber has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kidney Failure in Persons With Cystic Fibrosis

    by Mirjana Stevanovic, Todd A. MacKenzie, Asha M. Zimmerman, Martha L. Graber

  • Open Access

    Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)

    by Hayrettin Yavuz, Manish Kumar, Himanshu Ballav Goswami, Uta Erdbrügger, William Thomas Harris, Sladjana Skopelja-Gardner, Martha Graber, Agnieszka Swiatecka-Urban

    As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a significant comorbidity that is increasingly linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes, yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary extracellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease management in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.


  • Open Access

    Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD)

    by Hayrettin Yavuz, Manish Kumar, Himanshu Ballav Goswami, Uta Erdbrügger, William Tom Harris, Sladjana Skopelja-Gardner, Martha Graber, Agnieszka Swiatecka-Urban

    As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a sig-nificant comorbidity that increasingly is linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary ex-tra-cellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease man-agement in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.

  • Open Access

    End Stage Kidney Disease in Cystic Fibrosis

    by Mirjana Stevanovic, Todd A MacKenzie, Asha M Zimmerman, Martha L Graber

    Background: Cystic fibrosis (CF) is a multisystem autosomal recessive disease caused by mutations in the cystic fibrosis transduction regulator (CFTR). The CFTR is expressed in all renal tubular segments. Tubular functional abnormalities as well as renal histologic changes are recognized in people with cystic fibrosis (CF). Chronic kidney disease (CKD) occurs in CF at greater frequency than in the non-CF population. The prevalence and characteristics of end stage kidney disease (ESKD) in the cystic fibrosis population have not previously been described. Methods: We used data supplied by the US Renal Data System (USRDS) to compare persons with ESKD and CF with those with ESKD who did not have a diagnosis of CF. We used linear and logistic regression, propensity score-matched Kaplan-Meier survival curves, and log-rank tests. Results: The prevalence of ESKD was approximately thirty times higher than predicted in the general US population. Diabetes was more frequently a diagnosis in people with CF, but was approximately half as frequently the primary cause of ESKD than in those without CF. Complications of transplantation, particularly of lung, were rarely the cause of ESKD in those without CF but were the second most frequent etiology of ESKD in people with CF. Drugs and medications, interstitial nephritis and acute kidney injury (AKI) were more frequent primary causes in those with CF. Hypertension, cystic kidney disease, and glomerulonephritis were less frequent in those with CF. Mortality and survival with ESKD were not significantly different between those with CF and ESKD and those with ESKD who did not have CF. Diabetes mellitus and complications of lung transplantation as the primary cause of ESKD, but not lung transplant status, were associated with significantly shorter survival with ESKD in people with CF. Conclusions: People living with CF have a markedly higher prevalence of ESKD than the general United States population. The profile of primary causes of ESKD differed significantly from that of the non-CF population. Diabetes mellitus was approximately half as frequently the primary cause of ESKD in those with CF. Complications of solid organ transplant, particularly lung, were the second most frequent primary cause of ESKD in people with CF. Survival with ESKD was not significantly different between those who did and did not have CF. The diagnosis of diabetes mellitus, and complications of lung transplantation as the primary cause of ESKD, but not lung transplant status, were associated with significantly shorter survival with ESKD in people with CF. It is our aim that these findings will promote awareness of kidney disease in persons living with CF and will encourage prevention of acute kidney injury (AKI), early detection and intervention in CKD, and preemptive referral to nephrology and transplant centers.


  • Open Access

    Outcomes of Kidney Transplantation in Cystic Fibrosis

    by Mirjana Stevanovic, Todd A MacKenzie, Asha Zimmerman, Martha L Graber

    Background Cystic fibrosis (CF) is a chronic multisystem disease with features including recurrent pulmonary infection, bronchiectasis, malnutrition, and alterations in drug metabolism which may discourage referral and listing for kidney transplantation. Although no specific renal phenotype is identified in CF, chronic kidney disease (CKD) occurs in young people and adults with CF with greater frequency than in the general population. The characteristics and outcomes of kidney transplantation in the CF population have not been previously described. Methods We used de-identified data supplied by the US Renal Data System (USRDS) to compare persons with end stage kidney disease (ESKD) with first kidney transplant, who did and did not have a diagnosis of CF. We compared demographic and clinical characteristics, mortality, patient survival, and death-censored graft survival using linear and logistic regression, multivariable logistic regression models, and Kaplan-Meier and log-rank tests with stratification/binning by propensity scores. Results Of those with dual diagnoses of CF and ESKD, half received a first kidney transplant. CF was independently associated with higher odds of receiving a living donor transplant. Those with a kidney transplant were younger than both those who did not have CF and those with CF without transplant and had higher odds of being female. Those with dual diagnoses of CF and ESKD had disproportionately lower odds of being identified as Black or African American relative to their representation in the population of all with CF and ESKD. Diabetes was more frequently a diagnosis and primary cause of ESKD in people with CF, but was approximately half as frequently the primary cause of ESKD as in those without CF. Complications of transplantation, particularly lung, were the second most frequent etiology of ESKD in people with CF. Overall survival with ESKD was 21.1 years for those with CF and 31.8 for those without CF. The survival benefit associated with transplant was 17.2 years for those with CF and 24.8 years for those without CF. Death censored median graft survival was significantly longer for those with CF, 20.4 vs 13.7 years. Conclusions CF is a chronic multisystem disease with features which may discourage referral and listing for kidney transplant. We used de-identified data from the USRDS datasets to describe the characteristics and outcomes of all unique individuals with the diagnosis of CF and first kidney transplant prevalent during the five-year period 2014 and 2018. Those with CF had similar odds to those without CF or receiving a first kidney transplant, and higher odds of receiving a living donor graft. Diabetes mellitus was significantly less frequently the primary cause of ESKD in those with CF and kidney transplant. Complications of solid organ transplant, particularly lung, were the second most frequent cause of ESKD in people with CF and kidney transplant. Median patient survival following the first kidney transplant was significantly shorter than for those who did not have CF, but was substantial, as was the survival advantage when compared to dialysis. Median graft survival was significantly longer for those with CF. It is our hope that this data will improve awareness of kidney disease in persons living with CF and their care teams, and encourage early referral to nephrology and transplant centers, and positive consideration of wait listing for kidney transplantation.